Securities class action alleges Inovio Pharmaceuticals misled on CELLECTRA manufacturing and INO‑3107 BLA timeline

Allegations Target CELLECTRA Manufacturing and INO-3107 BLA Timeline

A securities class action filed against Inovio Pharmaceuticals alleges the company made false or misleading statements and omitted material facts about the manufacturing readiness of its CELLECTRA electroporation device and the regulatory pathway for its INO-3107 therapeutic vaccine. The complaint, covering purchases from Oct. 10, 2023 through Dec. 26, 2025, contends Inovio misrepresented manufacturing capabilities and overstated the likelihood of submitting a Biologics License Application (BLA) to the U.S. Food and Drug Administration by the second half of 2024.

Plaintiffs assert that deficiencies in manufacturing for the CELLECTRA device undercut Inovio’s ability to support a timely BLA filing and that the company lacked sufficient information to justify INO-3107’s eligibility for accelerated approval. The suit focuses on whether internal development and manufacturing problems were properly disclosed to the market, particularly given that CELLECTRA is integral to delivery of the company’s DNA medicines and to generating the clinical data supporting a BLA for INO-3107, a candidate targeting diseases such as human papillomavirus (HPV).

The case highlights scrutiny on Inovio’s development program and the broader challenges biotechs face in pairing device readiness with regulatory filings. Observers note that disruptive or delayed device manufacturing can ripple into clinical supply, regulatory timing and the statutory evidentiary standards for accelerated approval, an expedited pathway that relies on surrogate or intermediate clinical endpoints. Inovio positions itself as a biotechnology company focused on DNA medicines to treat and protect against diseases such as HPV, and the litigation could affect perceptions of its operational execution and regulatory strategy.

Lead Plaintiff Deadline and Participation

Rosen Law Firm, which filed the notice, reminds potential class members that the deadline to move for lead plaintiff is April 7, 2026, and invites those who purchased Inovio securities during the class period to seek representation. Interested parties are directed to submit via the firm’s case portal, call the toll-free number, or email the contact provided for more information.

Counsel Profile and Advisory

Rosen Law emphasizes selection of experienced counsel and highlights its own track record in securities class actions, citing large recoveries and industry recognitions for its attorneys and founding partner. The notice also warns investors to be cautious because some firms only refer clients rather than directly litigate.